COLL — Collegium Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- $1.14bn
- $1.50bn
- $566.77m
- 85
- 67
- 96
- 96
Annual income statement for Collegium Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 297 | 310 | 277 | 464 | 567 |
| Cost of Revenue | |||||
| Gross Profit | 103 | 180 | 151 | 214 | 326 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 320 | 254 | 259 | 431 | 423 |
| Operating Profit | -23.7 | 56.2 | 17.6 | 33.3 | 143 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -22.7 | 27.6 | -3.37 | -28.8 | 75.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.7 | 26.8 | 71.5 | -25 | 48.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.7 | 26.8 | 71.5 | -25 | 48.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -22.7 | 26.8 | 76.2 | -25 | 48.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.679 | 0.761 | 1.98 | -0.046 | 1.64 |